DRKS00034124尚未招募不适用
Kidney Tumor Study München Klinik Bogenhausen
Klinik für Urologie, München Klinik Bogenhausen gGmbH0 个研究点目标入组 300 人开始时间: 2024年6月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Histopathological evidence of renal cell carcinoma
- •- Availability of the image data from the cross-sectional imaging (CT or MRI; CD, USB, internal clinic data storage)
- •- Primary operation in the Department of Urology at the Munich Clinic gGmbH
- •- Ability to give consent to participate in the study (for legally cared for patients by the legal carer)
排除标准
- •- Known, hereditary or acquired bleeding tendency (participation is possible if there is a medication-related bleeding tendency; the medication will be adjusted according to the recommendation of the initially ordering doctor or the responsible department in the hospital)
- •- Anatomical anomalies such as severe scoliosis or short stature that prevent a standardized approach
- •- Patients with urothelial carcinoma of the upper urinary tract (e.g. renal pelvic carcinoma)
研究者
相似试验
招募中
不适用
Kidney Tumor Study Klinikum Region HannoverC64Malignant neoplasm of kidney, except renal pelvisDRKS00031089Abteilung für Urologie am KRH Klinikum Siloah97
尚未招募
不适用
Mainz Kidney cancer observational Registry studyC64Malignant neoplasm of kidney, except renal pelvisDRKS00034452niversitätsmedizin Mainz - Klinik und Poliklinik für Urologie und Kinderurologie800
已完成
不适用
Detection of Urologic Cancers and Chronic Kidney Disease in Patients with COPDCOPDJPRN-UMIN000017299Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital400
Unknown
1 期
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)Renal Cell CancerNCT00184015University of Southern California50
进行中（未招募）
1 期
ORTH-REG Dwell-Time Studyrothelial cancerCTIS2023-505936-37-00Aarhus University Hospital101